575
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Insights into molecular docking and dynamics to reveal therapeutic potential of natural compounds against P53 protein

, ORCID Icon, , , , & ORCID Icon show all
Pages 8762-8781 | Received 04 Jul 2022, Accepted 11 Oct 2022, Published online: 25 Oct 2022
 

Abstract

P53 is eminent tumour suppressor protein that plays a prominent role in cell cycle arrest, DNA repair, senescence, differentiation and initiation of apoptosis. P53 is an attractive drug target and the high toxicity of some cancer chemotherapy drugs increase the demand for new anti-cancer drugs from natural products. In this current scenario, identification of promising anticancer compounds from natural sources by repurposing approach is still relevant for the early prevention and effective management of cancer. In present study, we docked natural compounds like podophyllotoxin, quercetin and rutin along standard drugs (MG-132 and Bay 61-3606) against p53 protein. ADME/T analysis predicted toxicity of phytochemicals and drugs. In silico docking analysis of podophyllotoxin, quercetin and rutin gave HDOCK docking scores of −187.87, −148. 97 and −143.85, whereas control drugs MG-132 and Bay 61-3606 showed docking scores of −159.59 and −140.71 against p53 respectively. AutoDock analysis of rutin and MG-132 showed highest binding affinity scores of −7.3 and −6.8 kcal/mol against p53. Molecular dynamic simulation for p53 protein displayed stable conformation and convergence. In this study, P53-rutin complex showed free binding energy score of 11.84 kcal/mol and P53-MG-132 complex reported free energy score of 16.3 kcal/mol. Protein contacts atlas gives non-covalent contacts framework by exploring interfaces of individual subunits and protein-ligand interactions. STRING tool predicts physical and functional interactions between proteins. The results of this study revealed that rutin and MG-132 could be promising inhibitors against targeted p53 protein and this could prove detrimental for molecular therapeutics and drug-designing strategies.

Communicated by Ramaswamy H. Sarma

Disclosure statement

The authors have read the manuscript and have no conflict of interest.

Institutional Review Board Statement

Not applicable.

Authors’ contribution

Conceptualization, A.A., B.A.M., M.U.R Methodology, A.A, Software, A.A., Validation, A.A., Formal analysis, A.A., B.A.M., Investigation, A.A., B.A.M., Writing – original draft preparation, A.A., B.A.M., I.M., Writing – review and editing., A.A., B.A.M., M.U.R., N.A.D., S.B.A., R.M.A visualisation., A.A., Supervision, M.U.R., N.A.D., S.B.A. All authors have read and agreed to the published manuscript version.

Data availability statement

All the data generated have been published in this manuscript.

Additional information

Funding

This research did not receive any funding or grant from any funding agency.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 61.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,074.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.